Channel Therapeutics Corp... (PTHS)
NYSE: PTHS
· Real-Time Price · USD
31.68
0.11 (0.35%)
At close: Sep 10, 2025, 3:59 PM
31.00
-2.16%
After-hours: Sep 10, 2025, 05:10 PM EDT
Company Description
Clinical-stage biopharma focused on ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum, plus NaV1.7 pain pipeline.
Resulted from merger of Channel Therapeutics with Ligand’s LNHC/Pelthos.
Channel Therapeutics Corporation
| Country | United States |
| IPO Date | Jul 2, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Francis Knuettel II, |
Contact Details
Address: 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 Durham, North Carolina United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | PTHS |
| Exchange | NYSE |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US1711261057 |
| Employer ID | - |
| SIC Code | n/a |